Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses.
Oncoimmunology
; 9(1): 1789284, 2020 07 08.
Article
in English
| MEDLINE | ID: covidwho-1066080
ABSTRACT
Amid controversial reports that COVID-19 can be treated with a combination of the antimalarial drug hydroxychloroquine (HCQ) and the antibiotic azithromycin (AZI), a clinical trial (ONCOCOVID, NCT04341207) was launched at Gustave Roussy Cancer Campus to investigate the utility of this combination therapy in cancer patients. In this preclinical study, we investigated whether the combination of HCQ+AZI would be compatible with the therapeutic induction of anticancer immune responses. For this, we used doses of HCQ and AZI that affect whole-body physiology (as indicated by a partial blockade in cardiac and hepatic autophagic flux for HCQ and a reduction in body weight for AZI), showing that their combined administration did not interfere with tumor growth control induced by the immunogenic cell death inducer oxaliplatin. Moreover, the HCQ+AZI combination did not affect the capacity of a curative regimen (cisplatin + crizotinib + PD-1 blockade) to eradicate established orthotopic lung cancers in mice. In conclusion, it appears that HCQ+AZI does not interfere with the therapeutic induction of therapeutic anticancer immune responses.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Azithromycin
/
COVID-19 Drug Treatment
/
Hydroxychloroquine
/
Neoplasms
Type of study:
Prognostic study
/
Randomized controlled trials
Topics:
Traditional medicine
Limits:
Animals
/
Female
/
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
Oncoimmunology
Year:
2020
Document Type:
Article
Affiliation country:
2162402X.2020.1789284
Similar
MEDLINE
...
LILACS
LIS